Is the Precipitation of Anxiety Symptoms Associated with Bolus Doses of Flumazenil a Barrier to Its Use at Low Continuous Doses in Benzodiazepine Withdrawal?
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Introduction: Benzodiazepines (BZDs) are used in the management of anxiety and sleep disorders; however, chronic use is associated with tolerance and dependence. During withdrawal, symptoms of anxiety are often severe and problematic for patients and may lead to relapse or maintenance on low doses of BZDs. Low, continuous doses of flumazenil reduce BZD withdrawal symptoms in several studies; however, bolus doses are known to induce anxiety and precipitate panic. Accordingly, this study aimed to determine whether continuous low-dose flumazenil is anxiogenic like bolus doses. Method: In a randomised control cross over design, participants received a continuous low-dose flumazenil infusion for eight days at an approximate rate of 4 mg/24 h or placebo before crossing over to the alternate study arm. Participants were able to request diazepam as needed. The primary outcome was the change in state anxiety levels. Trait anxiety was also recorded at baseline and one month after the flumazenil/placebo infusion period. Results: BZD use was significantly reduced in both groups. There were no significant differences between state anxiety and the 95% confidence interval showed no evidence of a clinically significant anxiogenic effect from low-dose flumazenil. Trait anxiety was significantly reduced one month after the infusion period. Conclusion: There is no evidence that continuous low-dose flumazenil infusion significantly increases state anxiety levels to a clinically significant level. Interestingly, flumazenil may decrease state anxiety during BZD withdrawal, unlike bolus doses of flumazenil. Flumazenil may have an anxiolytic effect on trait anxiety, which was evident one month after treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent RCTs have suggested that low-dose flumazenil may be effective for facilitating BZD discontinuation, especially among patients taking high doses of BZDs.124,125”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
State-Trait Anxiety Inventory for Adults
Spielberger, C. D. (2012) · PsycTESTS Dataset · doi:10.1037/t06496-000 · Cited by 3,479
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Benzodiazepine use, abuse, and dependence.
O’Brien, C. P. (2005) · PubMed · Cited by 539
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
(2004) · PubMed · Cited by 296
Nutt, D. J. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220033004 · Cited by 272 · cited 1×
“2 mg/day), anxiety [18–23] and panic attacks [24].”
BackgroundThe benzodiazepine withdrawal syndrome
PÉTURSSON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03743.x · Cited by 246 · cited 1×
“Withdrawal syndromes are associated with both low and high doses of BZDs, with symptoms including rebound anxiety, sleep disturbances, panic attacks, irritability, and in severe cases, seizures [11,12].”
BackgroundBasic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Bateson, A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396681 · Cited by 240
Vinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195 · cited 2×
“Tolerance to the sedative effects of BZDs typically occurs after two weeks of continued use [10], while tolerance to the anxiolytic effects rarely occurs [6].”
Background
Cited by
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“124,125 Despite these findings, the CGC had concerns about the high potential for refractory seizures, cardiac dysrhythmias, and other adverse effects when using flumaze-nil.”
Gallo, A. T., Addis, S., Martyn, V., Ramanathan, H., Wilkerson, G. K., Hood, S. D., Stampfer, H. G., & Hulse, G. K. (2022) · Behavioral Sciences · doi:10.3390/bs12110430
“Caution is advised if increasing the dose or delivery rate in any new devices or delivery systems, as the dose and rate in this study (4 mg/24 h) has data to support that it is unlikely to be anxiogenic [43], unlike bolus doses.”
BackgroundSelf-citation
Metadata
- Authors
- Gallo, A., MacDonald, T., Bennett, K., Basso-Hulse, G., & Hulse, G.
- Affiliations
- The University of Western Australia (AU)
- Griffith University (AU)
- Edith Cowan University (AU)
- Corresponding author
- Gallo, Alexander
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-10-08
- Volume
- 11
- Issue
- 19
- Pages
- 5948
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9573680
- OpenAlex
- W4303709762
- Cited by
- 2
- References
- 41
- Citations by year
- 2025: 1 · 2022: 1
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
- Australasian Journal of Paramedicine (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Griffith Research Online (submittedVersion, cc-by)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Keywords
- flumazenil, benzodiazepine withdrawal, anxiogenic effects, state anxiety, trait anxiety, bolus dosing, benzodiazepine dependence, diazepam, anxiolytic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is the Precipitation of Anxiety Symptoms Associated with Bolus Doses of Flumazenil a Barrier to Its Use at Low Continuous Doses in Benzodiazepine Withdrawal? https://app.cochat.ai/papers/10.3390/jcm11195948
- The paper
- Gallo, A., MacDonald, T., Bennett, K., Basso-Hulse, G., & Hulse, G. (2022). Is the Precipitation of Anxiety Symptoms Associated with Bolus Doses of Flumazenil a Barrier to Its Use at Low Continuous Doses in Benzodiazepine Withdrawal? Journal of Clinical Medicine. https://doi.org/10.3390/jcm11195948
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.